Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Oliver Ottmann, Giuseppe Saglio, Jane F. Apperley, Christopher Arthur, Eduardo Bullorsky, Aude Charbonnier, John F. Dipersio, Hagop Kantarjian, Hanna Jean Khoury, Dong Wook Kim, Diane Healey, Lewis Strauss, Jorge E. Cortes

Research output: Contribution to journalLetter

Original languageEnglish (US)
Article number88
JournalBlood Cancer Journal
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. / Ottmann, Oliver; Saglio, Giuseppe; Apperley, Jane F.; Arthur, Christopher; Bullorsky, Eduardo; Charbonnier, Aude; Dipersio, John F.; Kantarjian, Hagop; Khoury, Hanna Jean; Kim, Dong Wook; Healey, Diane; Strauss, Lewis; Cortes, Jorge E.

In: Blood Cancer Journal, Vol. 8, No. 9, 88, 01.09.2018.

Research output: Contribution to journalLetter

Ottmann, O, Saglio, G, Apperley, JF, Arthur, C, Bullorsky, E, Charbonnier, A, Dipersio, JF, Kantarjian, H, Khoury, HJ, Kim, DW, Healey, D, Strauss, L & Cortes, JE 2018, 'Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib', Blood Cancer Journal, vol. 8, no. 9, 88. https://doi.org/10.1038/s41408-018-0122-3
Ottmann, Oliver ; Saglio, Giuseppe ; Apperley, Jane F. ; Arthur, Christopher ; Bullorsky, Eduardo ; Charbonnier, Aude ; Dipersio, John F. ; Kantarjian, Hagop ; Khoury, Hanna Jean ; Kim, Dong Wook ; Healey, Diane ; Strauss, Lewis ; Cortes, Jorge E. / Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 9.
@article{dc1c6ae2d4394b9ab037f3d53da444b6,
title = "Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib",
author = "Oliver Ottmann and Giuseppe Saglio and Apperley, {Jane F.} and Christopher Arthur and Eduardo Bullorsky and Aude Charbonnier and Dipersio, {John F.} and Hagop Kantarjian and Khoury, {Hanna Jean} and Kim, {Dong Wook} and Diane Healey and Lewis Strauss and Cortes, {Jorge E.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/s41408-018-0122-3",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

AU - Ottmann, Oliver

AU - Saglio, Giuseppe

AU - Apperley, Jane F.

AU - Arthur, Christopher

AU - Bullorsky, Eduardo

AU - Charbonnier, Aude

AU - Dipersio, John F.

AU - Kantarjian, Hagop

AU - Khoury, Hanna Jean

AU - Kim, Dong Wook

AU - Healey, Diane

AU - Strauss, Lewis

AU - Cortes, Jorge E.

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85052925537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052925537&partnerID=8YFLogxK

U2 - 10.1038/s41408-018-0122-3

DO - 10.1038/s41408-018-0122-3

M3 - Letter

C2 - 30190469

AN - SCOPUS:85052925537

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 9

M1 - 88

ER -